admin
The clash over Rx Kids moved from op‑ed pages to a formal hearing this week, and it wasn’t exactly kumbaya. The Michigan House Oversight Committee, led by Rep. Jay DeBoyer, put the first‑in‑the‑nation cash assistance program under a microscope. Supporters waved a new Lancet Public Health study that links the program to better birth outcomes in Flint. Republicans waved questions about $300 million in public money, bookkeeping, and whether “trust” is a good substitute for rules when other people’s taxes are on the line.
What happened at the Oversight hearing
The committee hearing focused on how Rx Kids spends the mix of private grants and public funds routed through programs like TANF and state health dollars. Dr. Mona Hanna, Rx Kids’ director and a Michigan State University dean, defended the program and pointed to a peer‑reviewed study showing fewer preterm births, lower rates of low birthweight babies, and fewer NICU admissions in Flint after Rx Kids began. Lawmakers pressed on spending limits, eligibility checks, and the roughly $40 million in overhead that has been paid from public sources. Rep. Jay DeBoyer said the committee is “trying to determine if the program is a good use of taxpayer funds” and acknowledged investigators have only just begun looking for problems — not that they’ve found widespread fraud.
Questions Republicans kept asking
GOP members kept circling back to basic accountability. Who verifies eligibility? Can public dollars be spent on alcohol, drugs, or items not related to mother and baby? Does the program duplicate existing aid? And perhaps most pointed: could Rx Kids be a Trojan horse for guaranteed‑income experiments that expand well beyond pregnancy and infancy? Those are fair questions. When taxpayers are on the hook for roughly $300 million — even after private fundraising of about $86 million and more than 150 grants — “trust us” is not a budgetary control plan.
The Lancet study is good news — but not a get‑out‑of‑oversight card
No one should ignore the Lancet Public Health findings. The study analyzed thousands of births and reported an estimated 18% drop in preterm births, 27% fewer low birthweight babies, and about a 29% cut in NICU admissions associated with the program in Flint. Those are promising signals that targeted help during pregnancy can save lives and money. But promising results don’t erase the need for hard numbers on administration, eligibility, duplication with other aid, and long‑term sustainability. Evidence of benefit raises the stakes for credible oversight — not the reverse.
What comes next for taxpayers and lawmakers
The committee can do a few useful things: demand audits, require clear reporting on how public funds are used, and tighten rules so state money targets the neediest families without funding waste or mission creep. If the program really cuts preterm births and NICU stays, show the math — health savings versus public outlays — and make the funding transparent. If it doesn’t, lawmakers should be ready to pull the plug or redirect dollars where oversight and outcomes line up. Michigan deserves programs that help moms and babies, but it also deserves fiscal discipline. Trust is admirable; accountability is nonnegotiable.
